| Trial ID | Target | Intervention | Study type | Patient population |
|---|---|---|---|---|
| NCT04375384 | EGFR inhibitor | Cetuximab | Phase II treatment, non-randomized, open-label clinical trial | HNSCC patients with R/M after the failure or intolerance of the immunotherapeutic drug |
| NCT04326257 | LAG-3 CTLA4 PD-1 | Nivolumab + Relatlimab Nivolumab + Ipilimumab | Phase II, open-label, parallel arms trial | R/M HNSCC patients with preceding failure of immunotherapy with anti-PD-1 or PD-L1, having a high expression of LAG-3 and CTLA4 genes |
| NCT04428151 | RTK and VEGFR1 inhibitor PD-1 | Lenvatinib (E7080/MK-7902) Pembrolizumab (MK-3475) | Phase II, randomized, open-label, three-arm clinical trial | R/M HNSCC patients with the progressed disease after platinum therapy and immunotherapy (PD-1/ PD-L1 inhibitors) |
| NCT03283605 | PD-1 CTLA4 | Durvalumab (MEDI4736) + Tremelimumab + stereotactic body radiotherapy (SBRT) | Phase II, open-label, single group | HNSCC metastatic patients following prior treatment failures |
| NCT04555837 | Serine/threonine-protein kinase Aurora-A inhibitor PD-1 | Alisertib Pembrolizumab | A Phase I-II, open-label study | Retinoblastoma (Rb)-deficient, HPV+ HNSCC patients. |
| NCT03022409 | ATR inhibitor PARP inhibitor | Ceralasertib Olaparib | Phase I, randomized, open-label | Treatment naïve HNSCC patients |
| NCT04634825 | B7-H3 PD-1 LAG-3 | Enoblituzumab Enoblituzumab + Tebotelimab | Phase II, open-label, non-randomized | Patients with R/M HNSCC |
| NCT04193293 | PI3K inhibitor PD-1 | Duvelsib Pembrolizumab | Phase Ia/IIb multicentre, non-randomized, open-label study | Patients with R/M HNSCC |
| NCT03565783 | PD-1 | Cemiplimab | Phase II, open-label | Patients with stage III-IV R/M HNSCC before surgery |
| NCT03854032 | PD-1 IDO1 | Nivolumab BMS-986205 | Phase 2 Randomized, open-label | Stage II-IV HNSCC patients |
| NCT04080804 | PD-1 LAG-3 CTLA4 | Nivolumab + Relatlimab Nivolumab + Ipilimumab | Phase II Neoadjuvant study, randomized, open-label | Locally advanced resectable HNSCC patients prior to surgical resection |
| NCT03795610 | PI3Kγ inhibitor | IPI-549 | Phase II, open-label | Locally advanced HPV+ and HPV– HNSCC patients |
| NCT04144517 | IL-2 PD-1 | ALKS 4230 Pembrolizumab | Phase II, open-label | Patients with HNSCC prior treated with anti-PD-L1 therapy but not achieved a CR |
| NCT03336606 | OX40 agonist | MEDI0562 | Phase1, randomized, open-label | HNSCC patients prior to surgical resection |
| NCT04602013 | PD-1 | Sintilimab | Phase II, open-label, multicentre | Locally advanced OSCC patients |
| NCT03818061 | PD-L1 VEGF | Atezolizumab Bevacizumab | Phase II, multi-center, non-randomized | Advanced stage patients with recurrence of HNSCC |
| NCT04393506 | VEGFR2 inhibitor PD-1 | Apatinib Camrelizumab | Phase I, open-label | Patients with locally advanced and resectable OSCC |
| CTRI/2020/ 11/028953 | PD-1 | Nivolumab | Phase I and II, randomized group | HNSCC patients under palliative systemic therapy |
RTK: receptor tyrosine kinase; ATR: ataxia telangiectasia and Rad3-related; PARP: Poly (ADP-ribose) polymerase; B7-H3: CD276; DART: dual-affinity re-targeting; ALKS 4230: nemvaleukin Alfa; CR: complete response